Glaxosmi. Pharma

{
  "main_header": {
    "sid": 793005,
    "name": "Glaxosmi. Pharma",
    "stock_name": "Glaxosmi. Pharma",
    "full_name": "Glaxosmithkline Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/glaxosmi-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,349.65",
    "chg": -39.25,
    "chgp": "-1.64%",
    "dir": -1,
    "prev_price": "2,388.90",
    "mcapval": "39,804.49 Cr",
    "mcap": "Mid Cap",
    "scripcode": 500660,
    "symbol": "GLAXO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE159A01016",
    "curr_date": "May 20",
    "curr_time": "",
    "bse_nse_vol": "54.25 k",
    "exc_status": "Active",
    "traded_date": "May 20, 2026",
    "traded_date_str": "2026 05 20",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Falls 1.81%: Flat Quarterly Performance and Margin Pressure Weigh",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-falls-181-flat-quarterly-performance-and-margin-pressure-weigh-3994544",
        "imagepath": "",
        "date": "2026-05-16 15:07:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>May 11:</strong> Stock opens at Rs.2,435.95 amid broad market decline</p>\n                    <p><strong>May 13:</strong> Q4 FY26 results reveal margin compression despite strong ROE</p>\n                    <p><strong>May 14:</strong> Flat quarterly performance reported amid shifting financial trends</p>\n                    <p><strong>May 15:</strong> Week closes at Rs.2,439.75, down 1.81% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,484.70</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><d..."
      },
      {
        "title": "Has Glaxosmithkline Pharmaceuticals Ltd declared dividend?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/has-glaxosmithkline-pharmaceuticals-ltd-declared-dividend-3993643",
        "imagepath": "",
        "date": "2026-05-15 23:30:48",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has declared a dividend.\n\nDividend Details:\n- Percentage announced: 570%\n- Amount per share: 12 per share\n- Ex-date: Nov-07-2024\n\nDividend Yield: 0%\n\nTotal Returns by Period:\nIn the 3 Months period, the price return was -5.94%, the dividend return was 2.20%, resulting in a total return of -3.74%.\n\nIn the 6 Months period, the price return was -1.54%, the dividend return was 2.30%, leading to a total return of 0.76%.\n\nOver the 1 Year period, the price return was -15.05%, the dividend return was 2.05%, culminating in a total return of -13.0%.\n\nIn the 2 Years period, the price return was 22.8%, the dividend return was 4.28%, resulting in a total return of 27.08%.\n\nFor the 3 Years period, the price return was 90.57%, the dividend return was 10.19%, leading to a total return of 100.76%.\n\nIn the 4 Years period, the price return was 63.56%, the dividend return was 12.80%, culmina..."
      },
      {
        "title": "Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-glaxosmithkline-pharmaceuticals-ltd-latest-results-good-or-bad-3991731",
        "imagepath": "",
        "date": "2026-05-14 19:19:57",
        "description": "GlaxoSmithKline Pharmaceuticals Ltd's latest financial results for the quarter ended March 2026 present a mixed operational picture. The company reported net sales of ₹995.30 crores, reflecting a sequential decline of 4.41% compared to the previous quarter, marking the second consecutive quarter of revenue contraction. Year-on-year, however, net sales showed a modest growth of 2.15%.\n\nIn terms of profitability, the net profit for the same quarter was ₹277.86 crores, which also represented a sequential decline of 6.01% from the prior quarter. On a year-on-year basis, net profit exhibited a growth of 5.70%. The operating margin stood at 35.26%, slightly down from 35.66% in the previous quarter, indicating some pressure on profitability metrics despite maintaining a strong position relative to industry averages.\n\nThe company has demonstrated exceptional return on equity at 55.83%, highlighting its efficiency i..."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Reports Flat Quarterly Performance Amid Shifting Financial Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-reports-flat-quarterly-performance-amid-shifting-financial-trends-3990275",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Glaxosmithkline_fintrenddot_3990275.png",
        "date": "2026-05-14 08:00:11",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. The company’s financial trend score has declined sharply from 7 to 0 over the past three months, signalling a pause in revenue momentum and margin expansion that investors had come to expect from this mid-cap pharmaceutical player."
      },
      {
        "title": "GlaxoSmithKline Pharmaceuticals Q4 FY26: Margin Compression Clouds Strong ROE Performance",
        "link": "https://www.marketsmojo.com/news/result-analysis/glaxosmithkline-pharmaceuticals-q4-fy26-margin-compression-clouds-strong-roe-performance-3990052",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Glaxosmithkline_quaterlyResult_3990052.png",
        "date": "2026-05-13 20:48:04",
        "description": "GlaxoSmithKline Pharmaceuticals Ltd., the Indian subsidiary of global biopharma giant GSK Plc., reported a net profit of ₹277.86 crores for Q4 FY26, marking a decline of 6.01% quarter-on-quarter whilst posting a modest 5.70% year-on-year growth. The ₹41,704 crore mid-cap pharmaceutical company's shares traded at ₹2,406.85 on May 13, down 1.68% from the previous close, reflecting investor concerns over sequential margin compression despite the company maintaining an exceptional return on equity of 55.83%."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3987324",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Glaxosmithkline_mojoScore_3987324.png",
        "date": "2026-05-12 10:10:46",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3972085",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Glaxosmithkline_mojoScore_3972085.png",
        "date": "2026-05-01 10:10:29",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3953815",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_mojoScore_3953815.png",
        "date": "2026-04-20 10:10:48",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3939384",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_mojoScore_3939384.png",
        "date": "2026-04-09 10:10:32",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      }
    ],
    "total": 5180,
    "sid": "793005",
    "stock_news_url": "https://www.marketsmojo.com/news/glaxosmithkline-pharmaceuticals-793005"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "18-May-2026",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-May-2026",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Corporate Action-Board approves Dividend",
      "datetime": "13-May-2026",
      "details": "outcome of Meeting",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>570%</strong> dividend, ex-date: 29 May 26",
          "dt": "2026-05-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
          "dt": "2018-09-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glaxosmithkline Pharmaceuticals Ltd Falls 1.81%: Flat Quarterly Performance and Margin Pressure Weigh

2026-05-16 15:07:22

Key Events This Week

May 11: Stock opens at Rs.2,435.95 amid broad market decline

May 13: Q4 FY26 results reveal margin compression despite strong ROE

May 14: Flat quarterly performance reported amid shifting financial trends

May 15: Week closes at Rs.2,439.75, down 1.81% for the week

Week Open

Rs.2,484.70

Week Close

Read full news article

Has Glaxosmithkline Pharmaceuticals Ltd declared dividend?

2026-05-15 23:30:48

Glaxosmithkline Pharmaceuticals Ltd has declared a dividend. Dividend Details: - Percentage announced: 570% - Amount per share: 12 per share - Ex-date: Nov-07-2024 Dividend Yield: 0% Total Returns by Period: In the 3 Months period, the price return was -5.94%, the dividend return was 2.20%, resulting in a total return of -3.74%. In the 6 Months period, the price return was -1.54%, the dividend return was 2.30%, leading to a total return of 0.76%. Over the 1 Year period, the price return was -15.05%, the dividend return was 2.05%, culminating in a total return of -13.0%. In the 2 Years period, the price return was 22.8%, the dividend return was 4.28%, resulting in a total return of 27.08%. For the 3 Years period, the price return was 90.57%, the dividend return was 10.19%, leading to a total return of 100.76%. In the 4 Years period, the price return was 63.56%, the dividend return was 12.80%, culmina...

Read full news article

Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?

2026-05-14 19:19:57

GlaxoSmithKline Pharmaceuticals Ltd's latest financial results for the quarter ended March 2026 present a mixed operational picture. The company reported net sales of ₹995.30 crores, reflecting a sequential decline of 4.41% compared to the previous quarter, marking the second consecutive quarter of revenue contraction. Year-on-year, however, net sales showed a modest growth of 2.15%. In terms of profitability, the net profit for the same quarter was ₹277.86 crores, which also represented a sequential decline of 6.01% from the prior quarter. On a year-on-year basis, net profit exhibited a growth of 5.70%. The operating margin stood at 35.26%, slightly down from 35.66% in the previous quarter, indicating some pressure on profitability metrics despite maintaining a strong position relative to industry averages. The company has demonstrated exceptional return on equity at 55.83%, highlighting its efficiency i...

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Reports Flat Quarterly Performance Amid Shifting Financial Trends

2026-05-14 08:00:11

Glaxosmithkline Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. The company’s financial trend score has declined sharply from 7 to 0 over the past three months, signalling a pause in revenue momentum and margin expansion that investors had come to expect from this mid-cap pharmaceutical player.

Read full news article

GlaxoSmithKline Pharmaceuticals Q4 FY26: Margin Compression Clouds Strong ROE Performance

2026-05-13 20:48:04

GlaxoSmithKline Pharmaceuticals Ltd., the Indian subsidiary of global biopharma giant GSK Plc., reported a net profit of ₹277.86 crores for Q4 FY26, marking a decline of 6.01% quarter-on-quarter whilst posting a modest 5.70% year-on-year growth. The ₹41,704 crore mid-cap pharmaceutical company's shares traded at ₹2,406.85 on May 13, down 1.68% from the previous close, reflecting investor concerns over sequential margin compression despite the company maintaining an exceptional return on equity of 55.83%.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-05-12 10:10:46

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-05-01 10:10:29

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-04-20 10:10:48

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-04-09 10:10:32

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

View All News